查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870799

噬菌體市場按應用、最終用戶、噬菌體類型、給藥途徑、製劑和生產過程分類－2025-2032年全球預測

Bacteriophage Market by Application, End User, Phage Type, Administration Route, Formulation, Production Process - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，噬菌體市場規模將達到 7,661 萬美元，複合年成長率為 5.44%。

關鍵市場統計數據
基準年 2024 5015萬美元
預計年份：2025年 5283萬美元
預測年份 2032 7661萬美元
複合年成長率 (%) 5.44%

噬菌體技術的策略應用及市場現況：研發、監管對話及影響跨產業應用路徑的因素

噬菌體科學已從微生物學的一個細分領域發展成為一個跨學科平台，涵蓋治療、診斷、農業、食品安全和動物健康等多個領域。基因組工程、製劑科學和可擴展生產平台的最新進展提高了基於噬菌體的解決方案的技術可行性，同時，快速病原體檢測和噬菌體分型技術的進步也增強了其在標靶干預方面的提案。因此，包括研究機構、醫院、食品加工商和農場在內的相關人員正在重新評估噬菌體在抗菌藥物管理和生物安全策略框架中的定位。

識別噬菌體科學、商業化、臨床應用和生產製造的變革性變化，以推動新的策略轉折點。

近年來，一系列變革性力量重新定義了噬菌體從實驗室概念轉變為可行的解決方案。精準基因組編輯技術的進步使得建構具有客製化宿主範圍和有效載荷的工程化噬菌體成為可能，從而提高了其療效和商業性吸引力。同時，快速診斷技術和改進的生物感測器整合透過縮短標靶時間和實現適應性治療策略，增強了噬菌體產品的臨床和農場應用價值。這些技術的融合正在推動噬菌體產品架構從「一刀切」模式轉變為更模組化和靶向的模式。

評估2025年美國關稅對噬菌體供應鏈、成本結構、國際貿易流量和國內生產的累積影響

2025年美國關稅政策可能對噬菌體產品的研發和分銷的經濟效益和物流產生重大影響。進口實驗室試劑、專用一次性系統和分析設備關稅帶來的成本壓力可能會增加研究機構和契約製造的上游工程支出。因此，籌資策略將轉向擁有國內生產能力和多元化採購管道的供應商，企業需要將關稅風險納入採購計畫和價格談判中。

關鍵細分市場分析突顯了應用、最終用戶、噬菌體分類、給藥途徑、製劑和生產方法對商業化的影響。

細分分析闡明了技術需求、採用趨勢和商業模式如何因應用、最終用戶、噬菌體類型、給藥途徑、製劑選擇和生產流程的不同而有所差異。在應用領域中，噬菌體的應用案例涵蓋農業、獸醫、診斷、食品安全和人類治療。在農業領域，重點在於植物保護、種子處理和土壤改良，每種應用對穩定性、給藥方法和監管證據的要求各不相同。獸醫學領域又細分為水產養殖、伴侶動物和畜牧業，每種領域對劑型、給藥途徑和停藥期都有顯著不同的考量。診斷領域包括生物感測器、病原體檢測和噬菌體分型，所有這些都強調靈敏度、速度以及與檢查室工作流程的整合。食品安全領域的應用主要集中在乳製品、肉類和農產品加工環節，需要在加工條件下進行嚴格的檢驗。在人類治療領域，該領域涵蓋皮膚病、胃腸道疾病、感染疾病和呼吸系統疾病，而感染疾病領域感染疾病和生物膜相關疾病帶來的獨特挑戰而進一步細分。

噬菌體技術的區域性洞察：美洲、歐洲、中東和非洲以及亞太市場差異化促進因素和障礙的比較

區域趨勢將對噬菌體解決方案的開發、監管和市場化產生重大影響。在美洲，監管機構和採購管道強調切實可行的臨床應用途徑，私部門對治療和農業應用領域的投資力度強勁。這促進了在報銷和採購獎勵存在的情況下快速推廣應用，但也使得活體生技藥品的監管變得複雜。在歐洲，監管環境各不相同。歐洲部分地區擁有完善的監管框架，有助於開展協調一致的臨床試驗和有條件核准，而該地區其他地區的監管成熟度則參差不齊。這些差異為區域中心的建立創造了機遇，這些中心可以支持跨司法管轄區的研究和供應鏈。

從競爭與合作的角度出發，深入分析噬菌體產業的能力、規模、智慧財產權趨勢和策略聯盟，並從公司洞察的角度探討其發展趨勢。

公司層面的趨勢揭示出，能力叢集、策略夥伴關係和智慧財產權組合決定著企業的競爭地位。擁有強大的研發能力、生產規模和監管經驗的公司最有利於將產品推進到臨床和商業管道。同時，規模小規模、專注於特定領域的生物技術公司和學術創業公司在噬菌體工程、遞送技術和細分應用領域取得了重大創新，從而構建了一個從上游藥物發現到下游規模化生產的充滿活力的生態系統。

為行業領導者提供切實可行的建議，以加速產品開發、降低商業化風險、最佳化生產製造並協調監管和市場策略。

行業領導者應優先考慮將技術開發與監管策略、生產準備和終端用戶參與相結合的綜合方法。首先，應投資進行嚴格的特性分析和穩定性測試，以滿足監管申報和採購競標的預期證據要件。這將降低後期階段的不確定性，並促進與監管機構的建設性對話。其次，生產藍圖應包含短期方案（利用契約製造組織 (CMO)）和中期計劃（建立本地生產能力）。這種雙軌制方法將有助於應對關稅風險和供應中斷。

本分析基於一套嚴謹的調查方法：詳盡的一手和二手研究、專家檢驗、資料三角驗證和情境分析。

本分析所依據的研究採用了混合方法，結合了與主要相關利益者的對話、全面的二手文獻綜述以及專家檢驗。主要研究包括對研究機構、契約製造、臨床網路、食品加工企業和監管事務部門的領導者進行結構化訪談，以了解實際的限制因素、採購促進因素和證據預期。這些訪談為假設的提出奠定了基礎，並有助於確定最具影響力的技術趨勢和市場動態的優先順序。

簡明扼要地總結了有關技術進步、監管勢頭、供應鏈韌性和相關人員策略要務的證據。

總之，噬菌體技術正處於一個轉折點，科學進步、製造創新、監管合規和市場需求正在匯聚，為治療、診斷、農業、食品安全和動物健康等領域創造實際機會。日趨成熟的工程技術，以及製劑和檢測技術的進步，正催生出更精準實用的解決方案。同時，不斷完善的法規結構也日益認可噬菌體產品的特殊性質。供應鏈設計和海關環境正在影響生產位置和採購方面的戰術性決策，凸顯了韌性和多元化的戰略重要性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 在醫院對抗多重抗藥性感染疾病的鬥爭中，噬菌體療法正擴大被用作抗生素的替代方案。
  • 利用先進基因組學技術開發工程噬菌體，以根除畜牧業中的特定細菌病原體
  • 全球對慢性傷口管理和糖尿病潰瘍治療的個人化噬菌體混合物的投資不斷增加
  • 監管協調工作旨在加速歐洲和美國市場噬菌體療法臨床試驗的核准流程。
  • 噬菌體衍生的酵素已成為污染防治的新型生物防治劑。
  • 透過生技Start-Ups與學術機構的合作，加速合成噬菌體庫的發現

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按應用分類的噬菌體市場

  • 農業
    • 植物保護
    • 種子處理
    • 土壤改良
  • 動物健康
    • 水產養殖
    • 伴侶動物
    • 家畜
  • 診斷
    • 生物感測器
    • 病原體檢測
    • 噬菌體分型
  • 食品安全
    • 乳製品
    • 肉類
    • 農產品
  • 人類治療
    • 皮膚科
    • 消化器官系統
    • 感染疾病
      • 細菌感染疾病
      • 生物膜相關
    • 呼吸系統

9. 依最終用戶分類的噬菌體市場

  • 畜牧場
  • 食品加工公司
  • 醫院
  • 研究所

第10章 依噬菌體類型分類的噬菌體市場

  • 改良噬菌體
  • 裂解噬菌體
  • 溫和噬菌體

11. 依給藥途徑分類的噬菌體市場

  • 吸入
  • 靜脈注射
  • 口服
  • 局部用藥

12. 依製劑分類的噬菌體市場

  • 膠囊製劑
  • 液體配方
  • 冷凍乾燥製劑

13. 依生產流程分類的噬菌體市場

  • 發酵
  • 合成製造

第14章 各地區噬菌體市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 噬菌體市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國噬菌體市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Locus Biosciences, Inc.
    • Armata Pharmaceuticals, Inc.
    • Adaptive Phage Therapeutics, Inc.
    • Intralytix, Inc.
    • Pherecydes Pharma SA
    • BiomX, Inc.
    • PhagoMed Biopharma GmbH
    • eligo Bioscience SAS
    • enBiotix, Inc.
    • Proteon Pharmaceuticals SA
Product Code: MRR-1A1A064C03A9

The Bacteriophage Market is projected to grow by USD 76.61 million at a CAGR of 5.44% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 50.15 million
Estimated Year [2025] USD 52.83 million
Forecast Year [2032] USD 76.61 million
CAGR (%) 5.44%

Strategic introduction to bacteriophage technologies and market realities shaping research, development, regulatory dialogue, and cross-sector adoption pathways

Bacteriophage science has evolved from a niche microbiological discipline into a multidisciplinary platform that intersects therapeutics, diagnostics, agriculture, food safety, and animal health. Recent advances in genomic engineering, formulation science, and scalable production platforms have increased the technical feasibility of phage-based solutions, while parallel improvements in rapid pathogen detection and phage typing have strengthened the value proposition for targeted interventions. Consequently, stakeholders across research institutions, hospitals, food processors, and farms are reassessing where bacteriophages fit within broader antimicrobial stewardship and biosecurity strategies.

At the same time, regulatory frameworks are gradually adapting to accommodate novel biologics that do not conform to traditional small-molecule paradigms. This transition imposes new evidentiary expectations while also opening pathways for conditional and compassionate use in selected settings. In addition, the growth of contract manufacturing and modular fermentation capabilities is lowering the barrier to scale for specialized producers, even as supply chain complexity persists for critical reagents and equipment. Taken together, these structural shifts are reshaping investment priorities, partnership models, and product roadmaps for companies operating in the bacteriophage ecosystem.

This introduction sets the stage for deeper analysis of the technological enablers, market-facing requirements, and cross-sector adoption dynamics that inform strategic decisions today and in the coming planning horizons.

Identifying transformative shifts in bacteriophage science, commercialization, clinical acceptance, and manufacturing that are driving new strategic inflection points

In recent years a cluster of transformative forces has redefined how bacteriophages move from laboratory concepts to deployable solutions. Advances in precision genome editing have enabled engineered phages with tailored host ranges and payloads, increasing both efficacy and commercial attractiveness. Simultaneously, improvements in rapid diagnostics and biosensor integration have strengthened the clinical and on-farm utility of phage products by reducing time-to-target and enabling adaptive treatment strategies. These technological convergences are catalyzing a shift from one-size-fits-all approaches to more modular, targeted product architectures.

Operationally, there is an accelerating emphasis on manufacturing robustness and formulation stability, with encapsulation and lyophilization techniques extending shelf life and enabling broader routes of administration. This capacity expansion is occurring alongside new regulatory dialogues that emphasize safety, traceability, and post-market surveillance, thereby influencing trial design and go-to-market sequencing. Moreover, cross-sector collaborations-linking academic labs, contract manufacturers, and clinical networks-are creating hybrid commercialization models that spread technical risk while concentrating expertise where it matters most.

As a result, incumbents and new entrants must reassess their value propositions, invest selectively in platform capabilities, and build flexible supply chain arrangements to capture emergent opportunities across therapeutics, diagnostics, agriculture, and food safety.

Assessing the cumulative impact of United States tariffs in 2025 on bacteriophage supply chains, cost structures, international trade flows, and domestic production

Tariff policy in the United States during 2025 has the potential to materially influence the economics and logistics of bacteriophage product development and distribution. Tariff-induced cost pressures on imported laboratory reagents, specialized single-use systems, and analytical instrumentation can increase upstream expenses for both research organizations and contract manufacturers. Consequently, procurement strategies are likely to pivot toward suppliers with domestic capacity or diversified sourcing arrangements, and companies will need to incorporate tariff risk into procurement planning and price negotiations.

Beyond direct cost impacts, tariffs can alter cross-border collaboration patterns. When import duties raise the cost of key inputs or finished goods, organizations may accelerate domestic partnerships or invest in local manufacturing to preserve margins and maintain supply continuity. This trend is particularly relevant for high-value, temperature-sensitive formulations where logistics complexity already commands significant attention. Conversely, tariffs can reduce the competitiveness of exported phage-based products, prompting exporters to seek tariff mitigation through product localization, co-manufacturing agreements, or tariff classification strategies that favor lower-duty pathways.

Regulatory and procurement stakeholders should also consider the secondary effects of tariff regimes on innovation pipelines. Increased import costs may incentivize manufacturers to optimize production processes, reduce reliance on single-sourced components, and pursue synthetic or fermentation-based workflows that are less exposed to cross-border tariff volatility. In short, tariffs in 2025 are not simply a near-term cost issue; they are a catalyst for supply chain redesign, strategic localization, and operational resilience that will shape the bacteriophage landscape beyond an immediate fiscal cycle.

Key segmentation insights revealing how applications, end users, phage typologies, administration routes, formulations, and production methods influence commercialization

Segmentation analysis clarifies where technical requirements, adoption dynamics, and commercial models diverge across applications, end users, phage types, administration routes, formulation choices, and production processes. In the application domain, bacteriophage use cases span Agriculture, Animal Health, Diagnostics, Food Safety, and Human Therapeutics. Within Agriculture the emphasis is split among plant protection, seed treatment, and soil amendment, each demanding different stability, delivery, and regulatory evidence profiles. Animal Health subdivides into aquaculture, companion animals, and livestock, where dosage forms, route of administration, and withdrawal considerations vary considerably. Diagnostics includes biosensors, pathogen detection, and phage typing, all of which place a premium on sensitivity, speed, and integration with laboratory workflows. Food Safety applications concentrate on dairy, meat, and produce pathways, requiring robust validation under processing conditions. Human Therapeutics covers dermatology, gastrointestinal, infectious diseases, and respiratory indications, with infectious diseases further differentiated by the specific challenges posed by bacterial infections and biofilm-associated conditions.

Complementing application-focused segmentation, end users encompass animal farms, food processing companies, hospitals, and research institutions, each with distinct procurement cycles, risk tolerances, and operational constraints. Phage typologies-engineered phages, lytic phages, and temperate phages-carry divergent regulatory and IP considerations that affect development timelines and partner selection. Administration routes including inhalation, intravenous, oral, and topical determine formulation strategy and cold chain needs, while formulation formats such as encapsulated, liquid, and lyophilized presentations influence shelf life and logistics. Finally, production choices between fermentation and synthetic manufacturing govern scalability, cost structure, and upstream supply dependencies. Together these segmentation layers create a complex matrix of product design and go-to-market options, and they underscore the importance of aligning technical capabilities with the specific requirements of target applications and end users.

Regional insights highlighting differentiated drivers and barriers across the Americas, Europe Middle East and Africa, and Asia Pacific markets for bacteriophage technologies

Regional dynamics materially affect how bacteriophage solutions are developed, regulated, and adopted across different markets. In the Americas regulatory agencies and procurement channels emphasize pragmatic pathways for clinical access, and there is strong private-sector investment in both therapeutic and agricultural applications. This results in rapid adoption in contexts where reimbursement or procurement incentives exist, but also requires navigation of complex federal and state-level oversight for live biologics. In Europe, Middle East & Africa, the regulatory landscape is heterogeneous: parts of Europe have advanced frameworks that facilitate clinical trial harmonization and conditional approvals, while other jurisdictions within the broader region present varying levels of regulatory maturity. These differences create opportunities for regional hubs that can support multi-jurisdictional studies and supply chains.

In Asia-Pacific, the combination of large agricultural sectors, high-density aquaculture operations, and emerging biotech innovation clusters is driving a distinct set of use cases and commercialization approaches. Regulatory modernization in several Asia-Pacific markets is accelerating local clinical workstreams and domestic manufacturing capacity, which in turn supports faster on-the-ground deployment. Across all regions there is a consistent premium on building local evidence of efficacy and safety, addressing logistics and cold chain challenges, and establishing trusted distribution channels. Moreover, regional procurement policies and tariff environments influence where organizations choose to site production and how they structure cross-border partnerships.

Competitive and collaborative company insights emphasizing capabilities, scale, intellectual property trends, and strategic partnerships shaping the bacteriophage landscape

Company-level dynamics reveal a landscape where capability clusters, strategic partnerships, and IP portfolios determine competitive positioning. Firms that combine robust R&D operations with manufacturing scale and regulatory experience are best positioned to move products into clinical and commercial channels. At the same time, smaller specialized biotechs and academic spinouts contribute critical innovation around phage engineering, delivery technologies, and niche applications, creating a vibrant ecosystem of upstream discovery and downstream scale-up.

Partnership models are particularly important: contract development and manufacturing organizations, diagnostic integrators, and agriculture-focused distributors provide the operational muscle that enables innovators to reach end users. Intellectual property strategies matter not only for protecting engineered constructs but also for securing freedom to operate around manufacturing processes and formulation technologies. Additionally, companies that proactively engage with regulatory agencies and invest in transparent safety and surveillance programs tend to reduce commercialization timelines and build trust with purchasing decision-makers.

Finally, access to capital and the ability to demonstrate reproducible manufacturing and clinical evidence remain critical gating factors. Investors and partners are increasingly looking for demonstrable translational milestones, credible risk mitigation plans, and the operational readiness to scale production while maintaining stringent quality control.

Actionable recommendations for industry leaders to accelerate development, de-risk commercialization, optimize manufacturing, and align regulatory and market strategies

Industry leaders should prioritize an integrated approach that links technology development with regulatory strategy, manufacturing readiness, and end-user engagement. First, invest in rigorous characterization and stability studies that align with anticipated evidence requirements for regulatory submissions and procurement tenders. This reduces later-stage uncertainty and facilitates constructive dialogue with authorities. Second, design manufacturing roadmaps that include both short-term options through contract manufacturing organizations and medium-term plans for localized capacity; such dual-track approaches help manage tariff exposures and supply interruptions.

Third, pursue targeted partnerships that connect discovery teams with distribution channels in hospitals, food processing, and agricultural sectors. These relationships accelerate adoption by embedding phage solutions into existing operational workflows and by generating real-world performance data. Fourth, adopt a modular product architecture that accommodates different administration routes and formulation formats, thereby increasing addressable use cases while streamlining development effort. Finally, build a transparent post-market surveillance framework to monitor efficacy, resistance patterns, and safety, and use that evidence to refine indications, dosing strategies, and messaging to payers and procurement bodies.

Taken together, these recommendations support de-risked commercialization, scalable manufacturing, and credible engagement with regulators and end users, enabling organizations to convert scientific potential into sustained impact.

Robust research methodology detailing primary and secondary approaches, expert validation, data triangulation, and scenario analysis used to underpin findings

The research underpinning this analysis used a mixed-methods approach combining primary stakeholder engagement with exhaustive secondary review and expert validation. Primary research included structured interviews with leaders in research institutions, contract manufacturing, clinical networks, food processing operations, and regulatory affairs to capture real-world constraints, procurement drivers, and evidence expectations. These interviews informed hypothesis generation and helped prioritize the most consequential technology and market dynamics.

Secondary research encompassed peer-reviewed literature, regulatory guidance documents, patent filings, and publicly available technical briefs to map technological trajectories and historical precedent. Data triangulation methods were applied to reconcile differing perspectives, and scenario analysis was used to stress-test assumptions about supply chain shocks, regulatory timelines, and adoption velocity. Expert panels provided iterative validation of key findings and guided the construction of strategic recommendations, while methodological transparency was maintained through documented interview protocols, source logs, and a reproducible analytical framework.

This blended methodology ensures the conclusions are grounded in empirical observation, validated by domain experts, and robust to a range of plausible futures, thereby supporting actionable decision-making for executives and investors.

Concise conclusion synthesizing evidence on technological progress, regulatory momentum, supply chain resilience, and strategic imperatives for stakeholders

In conclusion, bacteriophage technologies are at an inflection point where scientific progress, manufacturing innovation, regulatory adaptation, and market demand converge to create tangible opportunities across therapeutics, diagnostics, agriculture, food safety, and animal health. The maturation of engineering techniques, coupled with advances in formulation and detection technologies, enables more precise and deployable solutions, while evolving regulatory frameworks are gradually accommodating the special characteristics of phage-based products. Supply chain design and tariff environments will influence tactical decisions about production siting and sourcing, underscoring the strategic importance of resilience and diversification.

Companies that succeed will be those that align rigorous technical evidence with pragmatic manufacturing plans, proactive regulatory engagement, and deep end-user partnerships. By adopting modular product architectures, investing in demonstrable safety and surveillance programs, and building flexible supply chains, organizations can move from proof-of-concept to routine deployment. Ultimately, the most consequential progress will stem from integrated approaches that convert scientific capability into operationally reliable, economically viable, and clinically or operationally effective solutions for the stakeholders who depend on them.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of phage therapy as an alternative to antibiotics in hospitals battling multidrug-resistant infections
  • 5.2. Development of engineered bacteriophages using advanced genomics for targeted bacterial pathogen eradication in livestock farming
  • 5.3. Increasing investment in personalized phage cocktails for chronic wound management and diabetic ulcer treatment globally
  • 5.4. Regulatory harmonization initiatives facilitating accelerated approval pathways for clinical phage therapy trials in Western markets
  • 5.5. Emergence of phage-derived enzymes as novel biocontrol agents to address contamination in food processing and preservation
  • 5.6. Collaborations between biotech startups and academic institutions to accelerate discovery of synthetic phage libraries

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bacteriophage Market, by Application

  • 8.1. Agriculture
    • 8.1.1. Plant Protection
    • 8.1.2. Seed Treatment
    • 8.1.3. Soil Amendment
  • 8.2. Animal Health
    • 8.2.1. Aquaculture
    • 8.2.2. Companion Animals
    • 8.2.3. Livestock
  • 8.3. Diagnostics
    • 8.3.1. Biosensors
    • 8.3.2. Pathogen Detection
    • 8.3.3. Phage Typing
  • 8.4. Food Safety
    • 8.4.1. Dairy
    • 8.4.2. Meat
    • 8.4.3. Produce
  • 8.5. Human Therapeutics
    • 8.5.1. Dermatology
    • 8.5.2. Gastrointestinal
    • 8.5.3. Infectious Diseases
      • 8.5.3.1. Bacterial Infections
      • 8.5.3.2. Biofilm Associated
    • 8.5.4. Respiratory

9. Bacteriophage Market, by End User

  • 9.1. Animal Farms
  • 9.2. Food Processing Companies
  • 9.3. Hospitals
  • 9.4. Research Institutions

10. Bacteriophage Market, by Phage Type

  • 10.1. Engineered Phages
  • 10.2. Lytic Phages
  • 10.3. Temperate Phages

11. Bacteriophage Market, by Administration Route

  • 11.1. Inhalation
  • 11.2. Intravenous
  • 11.3. Oral
  • 11.4. Topical

12. Bacteriophage Market, by Formulation

  • 12.1. Encapsulated Formulation
  • 12.2. Liquid Formulation
  • 12.3. Lyophilized Formulation

13. Bacteriophage Market, by Production Process

  • 13.1. Fermentation
  • 13.2. Synthetic Manufacturing

14. Bacteriophage Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Bacteriophage Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Bacteriophage Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Locus Biosciences, Inc.
    • 17.3.2. Armata Pharmaceuticals, Inc.
    • 17.3.3. Adaptive Phage Therapeutics, Inc.
    • 17.3.4. Intralytix, Inc.
    • 17.3.5. Pherecydes Pharma SA
    • 17.3.6. BiomX, Inc.
    • 17.3.7. PhagoMed Biopharma GmbH
    • 17.3.8. eligo Bioscience SAS
    • 17.3.9. enBiotix, Inc.
    • 17.3.10. Proteon Pharmaceuticals S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BACTERIOPHAGE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BACTERIOPHAGE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BACTERIOPHAGE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BACTERIOPHAGE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS BACTERIOPHAGE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BACTERIOPHAGE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BACTERIOPHAGE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. BACTERIOPHAGE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BACTERIOPHAGE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BACTERIOPHAGE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BACTERIOPHAGE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PLANT PROTECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SEED TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SOIL AMENDMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BACTERIOPHAGE MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BACTERIOPHAGE MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOSENSORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DAIRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BACTERIOPHAGE MARKET SIZE, BY MEAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BACTERIOPHAGE MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BACTERIOPHAGE MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BACTERIOPHAGE MARKET SIZE, BY BIOFILM ASSOCIATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BACTERIOPHAGE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ANIMAL FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FOOD PROCESSING COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BACTERIOPHAGE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BACTERIOPHAGE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENGINEERED PHAGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYTIC PHAGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TEMPERATE PHAGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BACTERIOPHAGE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BACTERIOPHAGE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BACTERIOPHAGE MARKET SIZE, BY ENCAPSULATED FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LIQUID FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BACTERIOPHAGE MARKET SIZE, BY LYOPHILIZED FORMULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BACTERIOPHAGE MARKET SIZE, BY FERMENTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BACTERIOPHAGE MARKET SIZE, BY SYNTHETIC MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BACTERIOPHAGE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BACTERIOPHAGE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS BACTERIOPHAGE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS BACTERIOPHAGE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS BACTERIOPHAGE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY AGRICULTURE, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY ANIMAL HEALTH, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY FOOD SAFETY, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 330. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY HUMAN THERAPEUTICS, 2025-2032 (USD MILLION)
  • TABLE 331. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 332. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 333. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY PHAGE TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 338. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 339. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 340. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 341. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2018-2024 (USD MILLION)
  • TABLE 342. LATIN AMERICA BACTERIOPHAGE MARKET SIZE, BY PRODUCTION PROCESS, 2025-2032 (USD MILLION)
  • TABLE 343. EUROPE, MIDDLE EAST & A